Topical agents for the treatment of atopic dermatitis

References

• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018 Jun 21;4(1):1. PubMed PMID: 29930242; eng.
   PubMed Web of Science ®Google Scholar
• Flohr C, Mann J. New insights into the epidemiology of childhood atopic dermatitis. Allergy. 2014 Jan;69(1):3–16. PubMed PMID: 24417229.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016 Mar 12;387(10023):1109–1122. PubMed PMID: 26377142.
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, et al. The burden of atopic dermatitis in US adults: health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018 Jan;78(1):54–61.e1. PubMed PMID: 29017738.
   PubMed Web of Science ®Google Scholar
• Eckert L, Gupta S, Amand C, et al. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017 Aug;77(2):274–279.e3. PubMed PMID: 28606711.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017 Nov–Dec;5(6):1519–1531. PubMed PMID: 28970084.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014 May-Jun;25(3):107–114. PubMed PMID: 24819283; PubMed Central PMCID: PMCPMC4118692.
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Leung DY. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003 Dec;112(6 Suppl):S128–39. PubMed PMID: 14657843.
   PubMedGoogle Scholar
• Dharmage SC, Lowe AJ, Matheson MC, et al. Atopic dermatitis and the atopic march revisited. Allergy. 2014 Jan;69(1):17–27. PubMed PMID: 24117677.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin barrier and immune dysregulation in atopic dermatitis: an evolving story with important clinical implications. J Allergy Clin Immunol Pract. 2014 Jul-Aug;2(4):371. PubMed PMID: 25017523.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. Exp Dermatol. 2018 Apr;27(4):409–417. PubMed PMID: 28266782.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Krueger JG, Guttman-Yassky E. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol. 2013 Feb;131(2):300–313. PubMed PMID: 22939651; PubMed Central PMCID: PMCPMC4281264.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017 Apr;139(4S):S65–S76. PubMed PMID: 28390479; PubMed Central PMCID: PMCPMC5405702.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. J Allergy Clin Immunol. 2015 Oct;136(4):941–951.e3. PubMed PMID: 26242300; PubMed Central PMCID: PMCPMC4946641.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Gonzalez J, Bonifacio KM, et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol. 2016 Jan;137(1):118–129 e5. PubMed PMID: 26441226.
   PubMed Web of Science ®Google Scholar
• Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. Ann Allergy Asthma Immunol. 2018 Sep 6 PubMed PMID: 30223113; eng. DOI:10.1016/j.anai.2018.08.024.
   PubMed Web of Science ®Google Scholar
• Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015 Nov;136(5):1254–1264. PubMed PMID: 26428954; eng.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013 Aug;132(2):361–370. PubMed PMID: 23777851; PubMed Central PMCID: PMCPMC3991240.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017 Oct;48:68–73. PubMed PMID: 28869867.
   PubMed Web of Science ®Google Scholar
• El S, Ad I, Lf E, et al. Update on epidemiology, diagnosis, and disease course of atopic dermatitis. Semin Cutan Med Surg. 2016 Jun;35(5 Suppl):S84–8. PubMed PMID: 27525380; eng.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Malajian D, Khattri S, et al. Petrolatum: barrier repair and antimicrobial responses underlying this “inert” moisturizer. J Allergy Clin Immunol. 2016 Apr;137(4):1091–1102.e7. PubMed PMID: 26431582.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Ungar B, Malik K, et al. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. J Allergy Clin Immunol. 2017 Oct;140(4):1032–1042e13. PubMed PMID: 28238742.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017 Oct;77(4):623–633. PubMed PMID: 28803668.
   PubMed Web of Science ®Google Scholar
• Malajian D, Guttman-Yassky E. New pathogenic and therapeutic paradigms in atopic dermatitis. Cytokine. 2015 Jun;73(2):311–318. PubMed PMID: 25542094.
   PubMed Web of Science ®Google Scholar
• Oliva M, Renert-Yuval Y, Guttman-Yassky E. The ‘omics’ revolution: redefining the understanding and treatment of allergic skin diseases. Curr Opin Allergy Clin Immunol. 2016 Oct;16(5):469–476. PubMed PMID: 27490125; eng.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Esaki H, Gonzalez J, et al. Alterations in B-cell subsets in pediatric patients with early atopic dermatitis. J Allergy Clin Immunol. 2017 Jul;140(1):134–144 e9. PubMed PMID: 27965110.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. J Allergy Clin Immunol. 2015 Jul;136(1):104–115e7. PubMed PMID: 25748064.
   PubMed Web of Science ®Google Scholar
• Esaki H, Ewald DA, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol. 2015 Jan;135(1):153–163. PubMed PMID: 25567045; PubMed Central PMCID: PMCPMC4452382.
   PubMed Web of Science ®Google Scholar
• Suarez-Farinas M, Ungar B, Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol. 2015 May;135(5):1218–1227. PubMed PMID: 25840722.
   PubMed Web of Science ®Google Scholar
• Danso MO, van Drongelen V, Mulder A, et al. TNF-alpha and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol. 2014 Jul;134(7):1941–1950. PubMed PMID: 24518171; eng.
   PubMed Web of Science ®Google Scholar
• Kim BE, Leung DY, Boguniewicz M, et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008 Mar;126(3):332–337. PubMed PMID: 18166499; PubMed Central PMCID: PMCPMC2275206.
   PubMed Web of Science ®Google Scholar
• Nograles KE, Zaba LC, Shemer A, et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol. 2009 Jun;123(6):1244–52.e2. PubMed PMID: 19439349; PubMed Central PMCID: PMCPMC2874584. eng.
   PubMed Web of Science ®Google Scholar
• Gutowska-Owsiak D, Schaupp AL, Salimi M, et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol. 2012 Feb;21(2):104–110. PubMed PMID: 22229441; eng.
   PubMed Web of Science ®Google Scholar
• Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009 Sep;124(3 Suppl 2):R7–R12. PubMed PMID: 19720210.
   PubMed Web of Science ®Google Scholar
• Egawa G, Kabashima K. Multifactorial skin barrier deficiency and atopic dermatitis: essential topics to prevent the atopic march. J Allergy Clin Immunol. 2016 Aug;138(2):350–358.e1. PubMed PMID: 27497277; eng.
   PubMed Web of Science ®Google Scholar
• Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol. 2010 Mar 15;184(6):3186–3190. PubMed PMID: 20147633; PubMed Central PMCID: PMCPMC2837507. eng.
   PubMed Web of Science ®Google Scholar
• Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018 Apr;27(4):327–331. PubMed PMID: 29524262; eng.
   PubMed Web of Science ®Google Scholar
• Bagci IS, Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018 Mar;141(3):858–866. PubMed PMID: 29366565; eng.
   PubMed Web of Science ®Google Scholar
• Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012 Dec;130(6):1344–1354. PubMed PMID: 22951056; PubMed Central PMCID: PMCPMC3991245. eng.
   PubMed Web of Science ®Google Scholar
• Szegedi K, Kremer AE, Kezic S, et al. Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol. 2012 Jun;21(6):431–436. PubMed PMID: 22621183; eng.
   PubMed Web of Science ®Google Scholar
• Boulos S, Yan AC. Current concepts in the prevention of atopic dermatitis. Clin Dermatol. 2018 Sep - Oct;36(5):668–671. PubMed PMID: 30217281; eng.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017 Jun;139(6):1723–1734. PubMed PMID: 28583445.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Leung DY. Safety of topical calcineurin inhibitors in atopic dermatitis: evaluation of the evidence. Curr Allergy Asthma Rep. 2006 Jul;6(4):270–274. PubMed PMID: 16822378; eng.
   PubMed Web of Science ®Google Scholar
• Elias PM. An appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin med Dermatol. 2009 Feb 9;2:1–3. PubMed PMID: 19779592; PubMed Central PMCID: PMCPMC2749313. eng.
   PubMedGoogle Scholar
• Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2016 Jul;138(1):169–178. PubMed PMID: 26948076.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014 Jul;71(1):116–132. PubMed PMID: 24813302; PubMed Central PMCID: PMCPMC4326095.
   PubMed Web of Science ®Google Scholar
• He A, Feldman SR, Fleischer AB. Trends in atopic dermatitis management: comparison of 1990–1997 to 2003–2012. J Drugs Dermatol. 2018 Feb 1;17(2):135–140. PubMed PMID: 29462220.
   PubMed Web of Science ®Google Scholar
• Papier A, Strowd LC. Atopic dermatitis: a review of topical nonsteroid therapy. Drugs Context. 2018;7:212521. PubMed PMID: 29632548; PubMed Central PMCID: PMCPMC5886549.
   PubMedGoogle Scholar
• Guttman-Yassky E, Hanifin JM, Boguniewicz M, et al. The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Exp Dermatol. 2018 Oct 17 PubMed PMID: 30332502; eng. DOI:10.1111/exd.13808.
   Web of Science ®Google Scholar
• Horii KA, Simon SD, Liu DY, et al. Atopic dermatitis in children in the United States, 1997–2004: visit trends, patient and provider characteristics, and prescribing patterns. Pediatrics. 2007 Sep;120(3):e527–34. PubMed PMID: 17766497.
   PubMed Web of Science ®Google Scholar
• Proudfoot LE, Powell AM, Ayis S, et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey. Br J Dermatol. 2013 Oct;169(4):901–909. PubMed PMID: 23855450.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014 Aug;71(2):327–349. PubMed PMID: 24813298; PubMed Central PMCID: PMCPMC4410179.
   PubMed Web of Science ®Google Scholar
• Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. J Allergy Clin Immunol Pract. 2013 Mar; 1(2):142–151. PubMed PMID: 24565453.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Supuran CT, Winum JY. Benzoxaborole compounds for therapeutic uses: a patent review (2010–2018). Expert Opin Ther Pat. 2018 Jun;28(6):493–504. PubMed PMID: 29727210; eng.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Crisaborole ointment 2%: a review in mild to moderate atopic dermatitis. Am J Clin Dermatol. 2017 Dec;18(6):837–843. PubMed PMID: 29076116; eng.
   PubMed Web of Science ®Google Scholar
• Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018 Mar;78(3S1):S43–S52. PubMed PMID: 29248522.
   PubMed Web of Science ®Google Scholar
• Del Rosso J, Friedlander SF. Corticosteroids: options in the era of steroid-sparing therapy. J Am Acad Dermatol. 2005 Jul;53(1 Suppl 1):S50–8. PubMed PMID: 15968264.
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess. 2000;4(37): 1–191. PubMed PMID: 11134919; PubMed Central PMCID: PMCPMC4782813.
   PubMedGoogle Scholar
• Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb;156(2):203–221. PubMed PMID: 17223859.
   PubMed Web of Science ®Google Scholar
• Bornhovd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol. 2001 Nov;45(5):736–743. PubMed PMID: 11606925.
   PubMed Web of Science ®Google Scholar
• Levy ML. Atopic dermatitis: understanding the disease and its management. Curr Med Res Opin. 2007 Dec;23(12):3091–3103. PubMed PMID: 17971284.
   PubMed Web of Science ®Google Scholar
• Simpson EL. Atopic dermatitis: a review of topical treatment options. Curr Med Res Opin. 2010 Mar;26(3):633–640. PubMed PMID: 20070141.
   PubMed Web of Science ®Google Scholar
• Munzenberger PJ, Montejo JM. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy. 2007 Jul;27(7):1020–1028. PubMed PMID: 17594208.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Paller AS, Eichenfield L, et al. Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis. J Am Acad Dermatol. 2005 Aug;53(2 Suppl 2):S186–94. PubMed PMID: 16021174.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC pediatrics. 2016 Jun 7;16:75. PubMed PMID: 27267134; PubMed Central PMCID: PMCPMC4895880. eng.
   PubMed Web of Science ®Google Scholar
• Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Invest Drugs. 2007 May;8(5):364–372. PubMed PMID: 17520865.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996 Jul;107(1):51–56. PubMed PMID: 8752839.
   PubMed Web of Science ®Google Scholar
• Jimenez JL, Punzon C, Navarro J, et al. Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J Pharmacol Exp Ther. 2001 Nov;299(2):753–759. PubMed PMID: 11602691; eng.
   PubMed Web of Science ®Google Scholar
• Maurice DH, Ke H, Ahmad F, et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov. 2014 Apr;13(4):290–314. PubMed PMID: 24687066; PubMed Central PMCID: PMCPMC4155750. eng.
   PubMed Web of Science ®Google Scholar
• Baumer W, Hoppmann J, Rundfeldt C, et al. Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets. 2007 Mar;6(1):17–26. PubMed PMID: 17352685.
   PubMedGoogle Scholar
• Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016 Sep;75(3):494–503.e6. PubMed PMID: 27417017; eng.
   PubMed Web of Science ®Google Scholar
• Zane LT, Kircik L, Call R, et al. Crisaborole topical ointment, 2% in patients ages 2 to 17 years with atopic dermatitis: a phase 1b, open-label, maximal-use systemic exposure study. Pediatr Dermatol. 2016 Jul;33(4):380–387. PubMed PMID: 27193740; PubMed Central PMCID: PMCPMC5084761.
   PubMed Web of Science ®Google Scholar
• Murrell DF, Gebauer K, Spelman L, et al. Crisaborole topical ointment, 2% in adults with atopic dermatitis: a phase 2a, vehicle-controlled, proof-of-concept study. J Drugs Dermatol. 2015 Oct;14(10):1108–1112. PubMed PMID: 26461821.
   PubMed Web of Science ®Google Scholar
• Tom WL, Van Syoc M, Chanda S, et al. Pharmacokinetic profile, safety, and tolerability of crisaborole topical ointment, 2% in adolescents with atopic dermatitis: an open-label phase 2a study. Pediatr Dermatol. 2016 Mar-Apr;33(2):150–159. PubMed PMID: 26777394.
   PubMed Web of Science ®Google Scholar
• Stein Gold LF, Spelman L, Spellman MC, et al. A phase 2, randomized, controlled, dose-ranging study evaluating crisaborole topical ointment, 0.5% and 2% in adolescents with mild to moderate atopic dermatitis. J Drugs Dermatol. 2015 Dec;14(12):1394–1399. PubMed PMID: 26659931.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non-steroidal, phosphodiesterase 4 inhibitor. Acta Derm Venereol. 2018 Apr 27;98(5):484–489. PubMed PMID: 29363715; eng.
   PubMed Web of Science ®Google Scholar
• Zane LT, Hughes MH, Shakib S. Tolerability of crisaborole ointment for application on sensitive skin areas: a randomized, double-blind, vehicle-controlled study in healthy volunteers. Am J Clin Dermatol. 2016 Oct;17(5):519–526. PubMed PMID: 27335049; PubMed Central PMCID: PMCPMC5045489 eng.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Call RS, Forsha DW, et al. Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis. J Am Acad Dermatol. 2017 Oct;77(4):641–649.e5. PubMed PMID: 28823881.
   PubMed Web of Science ®Google Scholar
• Anacor pharmaceuticals announces positive preliminary results from phase 2a Trial of AN2728 and AN2898 in atopic dermatitis. BusinessWire. 2015.
   Google Scholar
• Wakita H, Ohkuro M, Ishii N, et al. A putative antipruritic mechanism of the phosphodiesterase-4 inhibitor E6005 by attenuating capsaicin-induced depolarization of C-fibre nerves. Exp Dermatol. 2015 Mar;24(3):215–216. PubMed PMID: 25431172.
   PubMed Web of Science ®Google Scholar
• Ohba F, Nomoto M, Hojo S, et al. Safety, tolerability and pharmacokinetics of a novel phosphodiesterase inhibitor, E6005 ointment, in healthy volunteers and in patients with atopic dermatitis. J DermatolTreat. 2016;27(3):241–246. PubMed PMID: 26581111.
   Google Scholar
• Furue M, Kitahara Y, Akama H, et al. Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial. J Dermatol. 2014 Jul;41(7):577–585. PubMed PMID: 24942594.
   PubMed Web of Science ®Google Scholar
• Ohba F, Matsuki S, Imayama S, et al. Efficacy of a novel phosphodiesterase inhibitor, E6005, in patients with atopic dermatitis: an investigator-blinded, vehicle-controlled study. J Dermatolog Treat. 2016 Oct;27(5):467–472. PubMed PMID: 27080209.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Ellis CN, Frieden IJ, et al. OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2016 Aug;75(2):297–305. PubMed PMID: 27189825.
   PubMed Web of Science ®Google Scholar
• Nygaard U, Deleuran M, Vestergaard C. Emerging treatment options in atopic dermatitis: topical therapies. Dermatology. 2017;233(5):333–343.
   PubMed Web of Science ®Google Scholar
• Topical roflumilast in adults with atopic dermatitis. Clinicaltrials.gov. Bethesda (MD): US National Library of Medicine; 2015.
   Google Scholar
• Ahluwalia J, Udkoff J, Waldman A, et al. Phosphodiesterase 4 inhibitor therapies for atopic dermatitis: progress and outlook. Drugs. 2017 Sep;77(13):1389–1397. PubMed PMID: 28681318; eng.
   PubMed Web of Science ®Google Scholar
• Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013 Jul 1;2(3):e24137. PubMed PMID: 24069552; PubMed Central PMCID: PMCPMC3772104.
   PubMedGoogle Scholar
• Vestergaard C, Deleuran M, Gesser B, et al. Expression of the T-helper 2-specific chemokine receptor CCR4 on CCR10-positive lymphocytes in atopic dermatitis skin but not in psoriasis skin. Br J Dermatol. 2003 Sep;149(3):457–463. PubMed PMID: 14510975.
   PubMed Web of Science ®Google Scholar
• Vestergaard C, Deleuran M, Gesser B, et al. Thymus- and activation-regulated chemokine (TARC/CCL17) induces a Th2-dominated inflammatory reaction on intradermal injection in mice. Exp Dermatol. 2004 Apr;13(4):265–271. PubMed PMID: 15086343.
   PubMed Web of Science ®Google Scholar
• Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014 Oct;134(4):792–799. PubMed PMID: 25065719.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012 Apr 20;36(4):542–550. PubMed PMID: 22520847; PubMed Central PMCID: PMCPMC3499974.
   PubMed Web of Science ®Google Scholar
• Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010 Aug 11;7:41. PubMed PMID: 20701804; PubMed Central PMCID: PMCPMC2928212.
   PubMed Web of Science ®Google Scholar
• Krueger J, Clark JD, Suarez-Farinas M, et al. Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study. J Allergy Clin Immunol. 2016 Apr;137(4):1079–1090. PubMed PMID: 27059729.
   PubMed Web of Science ®Google Scholar
• Ports WC, Feldman SR, Gupta P, et al. Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design. J Drugs Dermatol. 2015 Aug;14(8):777–784. PubMed PMID: 26267721.
   PubMed Web of Science ®Google Scholar
• Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol. 2016 Oct 3;16(1):15. PubMed PMID: 27716172; PubMed Central PMCID: PMCPMC5048458.
   PubMedGoogle Scholar
• Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol. 2016 Nov;175(5):902–911. PubMed PMID: 27423107.
   PubMed Web of Science ®Google Scholar
• Punwani N, Burn T, Scherle P, et al. Downmodulation of key inflammatory cell markers with a topical janus kinase 1/2 inhibitor. Br J Dermatol. 2015 Oct;173(4):989–997. PubMed PMID: 26123031.
   PubMed Web of Science ®Google Scholar
• BS NA K, Papp K, Parish LC, et al. A phase 2, randomized, dose-ranging, vehicle and active-controlled study to evaluate the safety and efficacy of ruxolitinib cream in adult patients with atopic dermatitis, 1956. 27th EADV Conference; Paris; 2018.
   Google Scholar
• Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study. Br J Dermatol. 2018 Feb;178(2):424–432. PubMed PMID: 28960254.
   PubMed Web of Science ®Google Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017 Oct;137(10):2110–2119. PubMed PMID: 28595996.
   PubMed Web of Science ®Google Scholar
• Moura-Alves P, Fae K, Houthuys E, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature. 2014 Aug 28;512(7515):387–392. PubMed PMID: 25119038.
   PubMed Web of Science ®Google Scholar
• R. Bissonnette, Chen G.. Efficacy and safety of topical wbi-1001 in the treatment of atopic dermatitis: results from a phase 2a, randomized placebo-controlled clinical trial. Arch Dermatol. 2010;146(4):446–448.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Poulin Y, Zhou Y, et al. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial. Br J Dermatol. 2012 Apr;166(4):853–860. PubMed PMID: 22182053.
   PubMed Web of Science ®Google Scholar
• Peppers J, Paller AS, Maeda-Chubachi T, et al. A phase 2, randomized dose-finding study of tapinarof (gsk2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2018 Jan;80(1):89–98. PubMed PMID:305546.
   Web of Science ®Google Scholar
• Yanes DA, Mosser-Goldfarb JL. Emerging therapies for atopic dermatitis: the prostaglandin/leukotriene pathway. J Am Acad Dermatol. 2018 Mar;78(3S1):S71–S75. PubMed PMID: 29248523.
   PubMed Web of Science ®Google Scholar
• Pharmacodynamics of omiganan (CLS001) in patients with atopic dermatitis. Clinicaltrials.gov. Bethesda (MD): US National Library of Medicine; 2016.
   Google Scholar
• Ruiz L. Spherium’s Cyclatop (SP14019), safe and efficacious for the treatment of atopic dermatitis in adults and infants. 2018.
   Google Scholar
• Ruiz Avila L. SP14019-cyclatop. Pilot study to assess efficacy and safety of 5% topical cyclosporine A in atopic dermatitis. 27th EADV Conference; Paris; 2018.
   Google Scholar
• Draelos ZD. Antipruritic hydrogel for the treatment of atopic dermatitis: an open-label pilot study. Cutis. 2012 Aug;90(2):97–102. PubMed PMID: 22988654.
   PubMed Web of Science ®Google Scholar
• Pelgrift RY, Friedman AJ. Topical Hypochlorous Acid (HOCl). as a potential treatment of pruritus. Curr Dermatol Rep. 2013;2(3): 181–190. .
   Google Scholar
• Leung TH, Zhang LF, Wang J, et al. Topical hypochlorite ameliorates NF-kappaB-mediated skin diseases in mice. J Clin Invest. 2013 Dec;123(12):5361–5370. PubMed PMID: 24231355; PubMed Central PMCID: PMCPMC3859383.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. New therapies for atopic dermatitis: additional treatment classes. J Am Acad Dermatol. 2018 Mar;78(3S1):S76–S83. PubMed PMID: 29248520.
   PubMed Web of Science ®Google Scholar
• Nakamizo S, Egawa G, Honda T, et al. Commensal bacteria and cutaneous immunity. Semin Immunopathol. 2015 Jan;37(1):73–80. PubMed PMID: 25326105.
   PubMed Web of Science ®Google Scholar
• Hancock RE, Sahl HG. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006 Dec;24(12):1551–1557. PubMed PMID: 17160061.
   PubMed Web of Science ®Google Scholar
• Hata TR, Gallo RL. Antimicrobial peptides, skin infections, and atopic dermatitis. Semin Cutan Med Surg. 2008 Jun;27(2):144–150. PubMed PMID: 18620136; PubMed Central PMCID: PMCPMC2546601.
   PubMed Web of Science ®Google Scholar
• Friedland HD, Sharp DD, Erfle DJ Omiganan (MBI 226) 1% gel: a novel topical antimicrobial agent with a favorable safety profile. Abstract presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sept 14–17; Chicago (IL).
   Google Scholar
• Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Ann Allergy Asthma Immunol. 2018 Jan;120(1):34–41. PubMed PMID: 29126710; eng.
   PubMed Web of Science ®Google Scholar
• Jungersted JM, Scheer H, Mempel M, et al. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy. 2010 Jul;65(7):911–918. PubMed PMID: 20132155; eng.
   PubMed Web of Science ®Google Scholar
• Chang KCN, Shen Q, Oh IG, et al. Liver X receptor is a therapeutic target for photoaging and chronological skin aging. Mol Endocrinol (Baltimore, MD). 2008 Nov;22(11):2407–2419. PubMed PMID: 18787039; eng.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Makishima M, Choi M, et al. Induction of SREBP-1c mRNA by differentiation and LXR ligand in human keratinocytes. J Invest Dermatol. 2009 Jun;129(6):1395–1401. PubMed PMID: 19242521; eng.
   PubMed Web of Science ®Google Scholar
• Kim KH, Lee GY, Kim JI, et al. Inhibitory effect of LXR activation on cell proliferation and cell cycle progression through lipogenic activity. J Lipid Res. 2010 Dec;51(12):3425–3433. PubMed PMID: 20847297; PubMed Central PMCID: PMCPMC2975714. eng.
   PubMed Web of Science ®Google Scholar
• Joseph SB, Bradley MN, Castrillo A, et al. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell. 2004 Oct 15;119(2):299–309. PubMed PMID: 15479645; eng.
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, Dohlman AB, Malik K, et al. Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis: A randomized controlled trial. Ann Allergy Asthma Immunol. 2018 Jun;120(6):631–640.e11. PubMed PMID: 29567358.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014 Oct;134(4):818–823. PubMed PMID: 25282563; PubMed Central PMCID: PMCPMC4180007.
   PubMed Web of Science ®Google Scholar
• Horimukai K, Morita K, Narita M, et al. Application of moisturizer to neonates prevents development of atopic dermatitis. J Allergy Clin Immunol. 2014 Oct;134(4):824–830 e6. PubMed PMID: 25282564.
   PubMed Web of Science ®Google Scholar
• Rawlings AV, Canestrari DA, Dobkowski B. Moisturizer technology versus clinical performance. Dermatol Ther. 2004;17(Suppl 1):49–56. PubMed PMID: 14728699; eng.
   PubMedGoogle Scholar
• Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4(11): 771–788. PubMed PMID: 14572299.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Berry TM, Brown PA, et al. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol. 2010 Oct;63(4):587–593. PubMed PMID: 20692725; PubMed Central PMCID: PMCPMC3156679.
   PubMed Web of Science ®Google Scholar
• Lee M, Van Bever H. The role of antiseptic agents in atopic dermatitis. Asia Pac Allergy. 2014 Oct;4(4):230–240. PubMed PMID: 25379483; PubMed Central PMCID: PMCPMC4215429.
   PubMedGoogle Scholar
• Winter J, Ilbert M, Graf PC, et al. Bleach activates a redox-regulated chaperone by oxidative protein unfolding. Cell. 2008 Nov 14;135(4):691–701. PubMed PMID: 19013278; PubMed Central PMCID: PMCPMC2606091.
   PubMed Web of Science ®Google Scholar
• Chopra R, Vakharia PP, Sacotte R, et al. Efficacy of bleach baths in reducing severity of atopic dermatitis: A systematic review and meta-analysis. Ann Allergy Asthma Immunol. 2017 Nov;119(5):435–440. PubMed PMID: 29150071; PubMed Central PMCID: PMCPMC5726436. eng.
   PubMed Web of Science ®Google Scholar
• Devillers AC, Oranje AP. Efficacy and safety of ‘wet-wrap’ dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol. 2006 Apr;154(4):579–585. PubMed PMID: 16536797.
   PubMed Web of Science ®Google Scholar
• Wolkerstorfer A, Visser RL, De Waard van der Spek FB, et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: influence of corticosteroid dilution. Br J Dermatol. 2000 Nov;143(5):999–1004. PubMed PMID: 11069509.
   PubMed Web of Science ®Google Scholar
• Hindley D, Galloway G, Murray J, et al. A randomised study of “wet wraps” versus conventional treatment for atopic eczema. Arch Dis Child. 2006 Feb;91(2):164–168. PubMed PMID: 16308411; PubMed Central PMCID: PMCPMC2082699.
   PubMed Web of Science ®Google Scholar
• Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009 Mar;8(1):40–43. PubMed PMID: 19250165.
   PubMed Web of Science ®Google Scholar
• Chamlin SL, Kao J, Frieden IJ, et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol. 2002 Aug;47(2):198–208. PubMed PMID: 12140465.
   PubMed Web of Science ®Google Scholar
• Eberlein B, Eicke C, Reinhardt HW, et al. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2008 Jan;22(1):73–82. PubMed PMID: 18181976.
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol. 2009 Dec;8(12):1106–1111. PubMed PMID: 20027938.
   PubMed Web of Science ®Google Scholar
• Abramovits W, Boguniewicz M. Adult atopiclair study G. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006 Mar;5(3):236–244. PubMed PMID: 16573256.
   PubMedGoogle Scholar
• Draelos ZD. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. J Cosmet Dermatol. 2011;10(3):185–188.
   PubMed Web of Science ®Google Scholar
• Whiteley J, Emir B, Seitzman R, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016 Jun 21:1–7. PubMed PMID: 27240604. DOI: 10.1080/03007995.2016.1195733.
   PubMed Web of Science ®Google Scholar